Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1985 1
1989 1
1992 3
1993 2
1994 2
1995 1
1998 3
1999 1
2000 2
2001 1
2002 1
2003 3
2005 3
2006 1
2007 9
2008 5
2009 2
2010 7
2011 4
2012 7
2013 13
2014 4
2015 9
2016 11
2017 7
2018 12
2019 10
2020 7
2021 4
2022 4
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Results by year

Filters applied: . Clear all
Page 1
Acromegaly: pathogenesis, diagnosis, and management.
Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Fleseriu M, et al. Lancet Diabetes Endocrinol. 2022 Nov;10(11):804-826. doi: 10.1016/S2213-8587(22)00244-3. Epub 2022 Oct 6. Lancet Diabetes Endocrinol. 2022. PMID: 36209758 Review.
Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal expansions of differentiated somatotroph cells and are usually sporadic. ...Normalisation of IGF-1 and growth hormone are the primary therapeutic …
Growth hormone-secreting pituitary adenomas that cause acromegaly arise as monoclonal expansions of differentiat …
Diagnosis and Treatment of Acromegaly: An Update.
Ershadinia N, Tritos NA. Ershadinia N, et al. Mayo Clin Proc. 2022 Feb;97(2):333-346. doi: 10.1016/j.mayocp.2021.11.007. Mayo Clin Proc. 2022. PMID: 35120696 Review.
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion of insulin-like growth factor 1. ...Early diagnosis and adequate treatment are essential to mitigate excess mortality associated with …
Acromegaly is typically caused by a growth hormone-secreting pituitary adenoma, driving excess secretion …
Diagnosis and Treatment of Pituitary Adenomas: A Review.
Molitch ME. Molitch ME. JAMA. 2017 Feb 7;317(5):516-524. doi: 10.1001/jama.2016.19699. JAMA. 2017. PMID: 28170483 Review.
Growth hormone-secreting tumors account for 8% to 16% of tumors and usually present with enlargement of the lips, tongue, nose, hands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels and growth hormone levels; i …
Growth hormone-secreting tumors account for 8% to 16% of tumors and usually present with enlargement of the lips, tongu …
Acromegaly pathogenesis and treatment.
Melmed S. Melmed S. J Clin Invest. 2009 Nov;119(11):3189-202. doi: 10.1172/JCI39375. Epub 2009 Nov 2. J Clin Invest. 2009. PMID: 19884662 Free PMC article. Review.
Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly - a disorder of disproportionate skeletal, tissue, and organ growth. ...Somatostatin receptor (SSTR) ligands inhibit GH …
Dysregulated growth hormone (GH) hypersecretion is usually caused by a GH-secreting pituitary adenoma and leads …
Growth Hormone Excess: Implications and Management.
Dhaneshwar S, Shandily S, Tiwari V. Dhaneshwar S, et al. Endocr Metab Immune Disord Drug Targets. 2023;23(6):748-763. doi: 10.2174/1871530322666221012155533. Endocr Metab Immune Disord Drug Targets. 2023. PMID: 36237164 Review.
Acromegaly is described as the oversecretion of growth hormone (GH) and, subsequently, insulin-like growth factor 1 (IGF-1), ascribed in most cases to a pituitary adenoma. ...Timely diagnosis and further treatment decreased the mortality rate of …
Acromegaly is described as the oversecretion of growth hormone (GH) and, subsequently, insulin-like growth factor 1 (IG …
Editorial: Personalized management of acromegaly.
Tritos NA. Tritos NA. Front Endocrinol (Lausanne). 2023 May 19;14:1214152. doi: 10.3389/fendo.2023.1214152. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37274350 Free PMC article. No abstract available.
Management of hormone-secreting pituitary adenomas.
Mehta GU, Lonser RR. Mehta GU, et al. Neuro Oncol. 2017 Jun 1;19(6):762-773. doi: 10.1093/neuonc/now130. Neuro Oncol. 2017. PMID: 27543627 Free PMC article. Review.
Management of hormone-secreting pituitary adenomas involves a multidisciplinary approach that can incorporate surgical, medical, and/or radiation therapies. ...Consequently, understanding clinical features as well as therapeutic options in the c …
Management of hormone-secreting pituitary adenomas involves a multidisciplinary approach that can incorporate surgical, …
Molecular genetic testing in the management of pituitary disease.
Coopmans EC, Korbonits M. Coopmans EC, et al. Clin Endocrinol (Oxf). 2022 Oct;97(4):424-435. doi: 10.1111/cen.14706. Epub 2022 Mar 29. Clin Endocrinol (Oxf). 2022. PMID: 35349723 Review.
Genetic alterations in sporadic pituitary adenomas may include somatic mutations (e.g., GNAS, USP8). ...DESIGN: Review of the recent literature in the field of genetics of pituitary tumours. RESULTS: Genetic testing in the management of pituitary disease is r …
Genetic alterations in sporadic pituitary adenomas may include somatic mutations (e.g., GNAS, USP8). ...DESIGN: Review of the recent …
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors.
Bianchi A, Chiloiro S, Giampietro A, Gaudino S, Calandrelli R, Mazzarella C, Caldarella C, Rigante M, Gessi M, Lauretti L, De Marinis L, Olivi A, Pontecorvi A, Doglietto F. Bianchi A, et al. Front Endocrinol (Lausanne). 2023 May 3;14:1123267. doi: 10.3389/fendo.2023.1123267. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37206441 Free PMC article. Review.
Growth Hormone-secreting adenomas exhibits variable biological behavior and heterogeneous natural history, ranging from small adenomas and mild disease, to invasive and aggressive neoplasms with more severe clinical picture. Patients not cured or controlled a …
Growth Hormone-secreting adenomas exhibits variable biological behavior and heterogeneous natural history, ranging from …
Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly.
Haberbosch L, Strasburger CJ. Haberbosch L, et al. Arch Med Res. 2023 Dec;54(8):102884. doi: 10.1016/j.arcmed.2023.102884. Epub 2023 Sep 1. Arch Med Res. 2023. PMID: 37659952 Review.
Pegvisomant, the first and currently only clinically available growth hormone receptor antagonist, is an effective therapeutic option for the medical treatment of acromegaly, a rare disorder characterized by excessive growth hormone secretion. . …
Pegvisomant, the first and currently only clinically available growth hormone receptor antagonist, is an effective therapeu …
133 results